Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review.
Options
BORIS DOI
Date of Publication
December 2021
Publication Type
Article
Division/Institute
Contributor
Series
Climacteric
ISSN or ISBN (if monograph)
1369-7137
Publisher
Informa Healthcare
Language
English
Publisher DOI
PubMed ID
33709861
Uncontrolled Keywords
Description
Genitourinary syndrome of menopause (GSM) is a highly prevalent, not self-limiting condition displaying a major negative impact on sexual function and emotional well-being. Various non-hormonal and hormonal treatment options are available. Many women consider GSM treatment to be a short-term interval cure rather than a long-term or lifelong treatment. The aim of this systematic literature search was to assess the sustainability of vaginal estrogens for GSM treatment after treatment cessation. We found that objective GSM signs mostly deteriorated within approximately 4 weeks after vaginal estrogen treatment cessation, while vaginal estrogens had a more sustainable impact on subjective GSM symptoms up to 3-6 months. However, overall, scientific evidence on sustainability of vaginal estrogens was low. Thus, GSM treatment should not be considered a short-term interval cure but long-term therapy. Further studies in an internationally harmonized setting (Core Outcomes in Menopause [COMMA]) are needed.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
Weidlinger_Climacteric_2021_epub.pdf | text | Adobe PDF | 1.13 MB | publisher | published | ||
Weidlinger_Climacteric_2021_supplmat.pdf | text | Adobe PDF | 177.05 KB | publisher | supplemental |